At AOA Dx, their vision is to bring innovative, impactful and cost effective medical technologies from research and development into the hands of patients and providers.
WHAT MAKES THEM A VISIONARY BIOTECH
Due to a lack of tests and non-specific symptoms related to ovarian cancer, there is no good way to screen for tumors and start treatment before the disease spreads. Ovarian tumors are nearly impossible to detect until they are in their advanced stages. However, about 94% of patients live longer than five years when ovarian cancer is detected early–AOA's first-to-market liquid biopsy is expected to help reduce ovarian cancer deaths by half.
AOA is developing new technology to alter the way patients and providers approach early-stage ovarian cancer diagnosis. Their trademarked technology, Akrivis GD™ is a test that diagnoses by detecting tumor biomarkers and has shown promising results in preliminary testing for both pre and postmenopausal individuals.
On top of their liquid biopsy innovation, AOA works to bring research out of the laboratory and into the hands of practitioners and patients. What good is a breakthrough, after all, if it never gets to the people who need it most?
Co-Founders, Oriana Papin-Zoghbi, Alex Fisher and Anna Jeter have worked together for over 8 years, combining 30 years of experience bringing products from concept to commercialization across global markets.